Skip to main navigation Skip to search Skip to main content

Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy

  • Alejandro Jiménez-Sánchez
  • , Paulina Cybulska
  • , Katherine La Vigne Mager
  • , Simon Koplev
  • , Oliver Cast
  • , Dominique Laurent Couturier
  • , Danish Memon
  • , Pier Selenica
  • , Ines Nikolovski
  • , Yousef Mazaheri
  • , Yonina Bykov
  • , Felipe C. Geyer
  • , Geoff Macintyre
  • , Lena Morrill Gavarró
  • , Ruben M. Drews
  • , Michael B. Gill
  • , Anastasios D. Papanastasiou
  • , Ramon E. Sosa
  • , Robert A. Soslow
  • , Tyler Walther
  • Ronglai Shen, Dennis S. Chi, Kay J. Park, Travis Hollmann, Jorge S. Reis-Filho, Florian Markowetz, Pedro Beltrao, Hebert Alberto Vargas, Dmitriy Zamarin, James D. Brenton, Alexandra Snyder, Britta Weigelt, Evis Sala, Martin L. Miller

Research output: Contribution to journalArticlepeer-review

192 Scopus citations

Abstract

In metastatic cancer, the degree of heterogeneity of the tumor microenvironment (TME) and its molecular underpinnings remain largely unstudied. To characterize the tumor–immune interface at baseline and during neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC), we performed immunogenomic analysis of treatment-naive and paired samples from before and after treatment with chemotherapy. In treatment-naive HGSOC, we found that immune-cell-excluded and inflammatory microenvironments coexist within the same individuals and within the same tumor sites, indicating ubiquitous variability in immune cell infiltration. Analysis of TME cell composition, DNA copy number, mutations and gene expression showed that immune cell exclusion was associated with amplification of Myc target genes and increased expression of canonical Wnt signaling in treatment-naive HGSOC. Following NACT, increased natural killer (NK) cell infiltration and oligoclonal expansion of T cells were detected. We demonstrate that the tumor–immune microenvironment of advanced HGSOC is intrinsically heterogeneous and that chemotherapy induces local immune activation, suggesting that chemotherapy can potentiate the immunogenicity of immune-excluded HGSOC tumors.

Original languageEnglish
Pages (from-to)582-593
Number of pages12
JournalNature Genetics
Volume52
Issue number6
DOIs
StatePublished - 1 Jun 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy'. Together they form a unique fingerprint.

Cite this